News Overview

Aug. 9, 2017
News Release
Oncolys Receives Notice of Allowance for EU Patent Expanding OBP-601 IP Protection
Aug. 4, 2017
News Release
First Half of the Fiscal Year ending December 2017 Financial Results Presentation
Aug. 4, 2017
News Release
Oncolys Receives Notice of Allowance for Chinese Patent Expanding OBP-1101 (TelomeScan F35) IP Protection
Aug. 4, 2017
News Release
Announcement of Non-Operating Losses
Jul. 28, 2017
News Release
Enrollment of First Patient in Melanoma Phase II Clinical Trial for Telomelysin® (OBP-301) in the US
Jul. 24, 2017
Others
Telomelysin®-Radiation Combination Therapy Interim Data to be Presented at the 15th Annual Meeting of JSMO
Jul. 11, 2017
Others
Telomelysin®-Radiation Combination Therapy Interim Data to be Presented at the 23rd Annual Meeting of JSGCT
Jul. 11, 2017
Publications
The paper relating to Telomelysin® (OBP-301), "Role of zoledronic acid in oncolytic virotherapy: promotion of antitumor effect and prevention of bone destruction", was published in Cancer Science, the official journal of the Japanese Cancer Association.
Jul. 10, 2017
Others
Yasuo Urata, President & CEO of Oncolys BioPharma to Present at the 23rd Annual Meeting of JSGCT
Jul. 7, 2017
News Release
Enrollment of First Patient in Phase I Clinical Trial for Telomelysin® (OBP-301) –radiation combination therapy
Jul. 4, 2017
News Release
Oncolys Confirms OBP-1101(TelomeScan F35) US Patent Issued
Jun. 27, 2017
News Release
CTN submitted for an Investigator-Initiated Clinical Trial for Telomelysin® (OBP-301) - pembrolizumab combination therapy
Jun. 6, 2017
Others
Yasuo Urata, President & CEO of Oncolys BioPharma to present at the 23^rd Anti-Tumor Drug Development Forum in Tokyo – June 24, 2017
Jun. 2, 2017
News Release
Oncolys to participate in the Japan Pavilion, BIO 2017 International Convention in San Diego, USA - June 19-22, 2017.
May. 24, 2017
News Release
Oncolys' First Telomelysin® Phase I Clinical Trial in Japan Received IRB Approval
May. 2, 2017
News Release
Announcement of Non-Operating Losses
Apr. 7, 2017
Publications
The paper relating to TelomeScan® was published on Oncotarget
Mar. 29, 2017
News Release
Oncolys invests in a Washington University biotech venture specialized in vaccine development for Zika and emerging infectious diseases
Mar. 28, 2017
News Release
Announcement of a Joint Research Agreement with Osaka University for Next Generation Telomelysin®
Mar. 24, 2017
News Release
Oncolys signs a revised strategic alliance agreement for Telomelysin® (OBP-301) with Medigen Biotechnology Corp.
Mar. 21, 2017
Others
Preliminary clinical trial results with Telomescan® were presented at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco
Mar. 14, 2017
News Release
Oncolys Submitted CTN of the First Sponsor-Initiated Clinical Trial for Telomelysin® (OBP-301) in Japan
Feb. 8, 2017
News Release
Notice of Partial Amendments to the Articles of Incorporation
Feb. 8, 2017
News Release
Announcement of Non-Operating Losses and Extraordinary Losses
Feb. 3, 2017
News Release
Our oncolytic adenovirus Telomelysin was featured in BS TBS's program "No more fear!? Cancer Care Frontline (もう怖くない!? がん医療最前線)", broadcasted on 3 Feb 2017.
Jan. 23, 2017
News Release
The 13th Winter Conference Medicinal and Bioorganic Chemistry, CO. – Dr Bryan Smith, Deciphera Pharmaceuticals, LLC, to present "Detecting Circulating Tumor Cells in Clinical Trials - Making Circulating Tumor Cells Glow using a Telomerase-based Assay".
Nov. 30, 2016
News Release
Announcement of License Agreement for Telomelysin™ (OBP-301) in China
Nov. 4, 2016
News Release
Announcement of Non-Operating Income and Losses, Extraordinary Losses, and FY 2016 Earnings Forecast Revision
Oct. 20, 2016
Others
Announcement of a TelomeScan Joint Research Agreement with DNA Chip Research Inc.
Oct. 11, 2016
Others
Oncolys to co-host a sponsored symposium on "Cutting edge of Oncolytic Virus Immunotherapy" at The 54th Annual Meeting of Japan Society of Clinical Oncology in Yokohama, on 21st October 2016.
Aug. 31, 2016
News Release
Protocol Submission of OBP-301 (Telomelysin®) for Phase II Clinical Trial in the United States
Aug. 19, 2016
News Release
Notice of Establishment of Overseas Subsidiary in the US
Aug. 10, 2016
News Release
Announcement of Investigator-Initiated Trial Agreement with National Cancer Center Hospital East Using OBP-301
Jul. 15, 2016
News Release
Announcement of Financial Forecast for the First Half of the Fiscal Year Ending December 31, 2016
Jul. 5, 2016
News Release
Announcement of an OBP-301 Joint Research Agreement with Graduate School of Medicine, Nagoya University
Jun. 30, 2016
Others
Our longtime research collaborator, Okayama University, published its research on synergistic effects of OBP-301 (Telomelysin) with chemotherapeutic agents on osteosarcoma in "Scientific Reports" (Nature Publishing Group).
Jun. 30, 2016
Others
Our business partner, Liquid Biotech USA, Inc. announces collaboration with the University of Pennsylvania and funding of sponsored research agreement
Jun. 27, 2016
News Release
Notice of Allowance for Japanese Patent Expanding OBP-1101 (TelomeScan F35) IP Protection
Jun. 15, 2016
News Release
Announcement of a Joint Research Agreement with Graduate School of Medicine, Kyoto University
May. 31, 2016
News Release
Announcement of Option Agreement for Anti-HIV Drug OBP-601 (Censavudine®)
May. 26, 2016
News Release
Completion of Highest Single-Dose Level Clinical Trial of OBP-301 (Telomelysin®), Phase I/II in Taiwan and Korea
May. 25, 2016
News Release
OBP-1101(TelomeScan F35) research by Dr. Tanemura awarded in the 70th Meeting of the Japanese Society for Advancement of Surgical Techniques (JSAST)
May. 20, 2016
News Release
Announcement of Letter of Intent for OBP-301(Telomelysin®) license in China
May. 20, 2016
News Release
Announcement of Amended License Agreement for OBP-1101(TelomeScan F35)
May. 6, 2016
News Release
Oncolys BioPharma proudly participates in BIOtech Japan 2016 from 11th to 13th May at Tokyo Big Sight
Apr. 6, 2016
Others
Our business partner,LIQUID BIOTECH USA, INC. announcing a completion of Proof-Of-Concept (POC) clinical study that triggers a $1M milestone payment from Oncolys BioPharma, Inc.
Mar. 19, 2016
News Release
The 88th Annual Meeting of Japanese Gastric Cancer Association - OBP-301 (Telomelysin®) introduced in a luncheon seminar "The trends of new drug development for the treatment of advanced gastric cancer"
Mar. 3, 2016
Publications
The paper relating to TelomeScan® was published on"Molecular Therapy — Methods & Clinical Development"
Feb. 23, 2016
News Release
The 23rd International Annual Molecular Med TRI-CON 2016, San Francisco, CA. - our TelomeScan® research collaborator Dr. Dorsey (Department of Radiation Oncology, University of Pennsylvania) to hold a luncheon seminar on Wed 9 March, to discuss the association of "telomerase-dependent CTC findings" with treatment response in a variety of cancer patient populations.
Feb. 22, 2016
Others
Our business partner,LIQUID BIOTECH USA, INC. was selected as a finalist in the 2016 Enterprise Awards Life Sciences Startup Category by PACT.
Jan. 19, 2016
News Release
Our diagnostic business was featured in TV TOKYO's program "Medical office where the chief physician is found in", broadcasted on 18 Jan 2016.
pagetop